/
VIR
$10.52+$0.08 (+0.77%)live
Change$-44.02
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.8B
169M shares
52-week range
$4.75 – $11.94
80% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
P/S (TTM)
5.9
Vir Biotechnology, Inc. Common Stock
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
www.vir.bio- Employees
- 367
- IPO / List date
- Oct 11, 2019
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds VIR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 761,364 | $6.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded VIR yet.
